Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials

被引:8
|
作者
Bavishi, Chirag [1 ]
Chugh, Yashasvi [2 ,3 ]
Kimura, Takeshi [4 ]
Natsuaki, Masahiro [5 ]
Kaiser, Christoph [6 ]
Gordon, Paul [1 ]
Aronow, Herbert D. [1 ]
Abbott, Jinnette Dawn [1 ]
机构
[1] Rhode Isl Hosp, Lifespan Cardiovasc Inst, Providence, RI 02903 USA
[2] Mt Sinai St Lukes Hosp, New York, NY USA
[3] Mt Sinai West Hosp, New York, NY USA
[4] Kyoto Univ, Grad Sch Med, Sakyo Ku, Kyoto, Japan
[5] Saga Univ, Saga, Japan
[6] Univ Hosp, Basel, Switzerland
关键词
Biodegradable polymer; Durable polymer; Drug-eluting stent; Diabetes; EVEROLIMUS; SAFETY; THROMBOSIS; OUTCOMES; EFFICACY; LEADERS;
D O I
10.1093/ehjqcco/qcz031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The biodegradable polymer drug-eluting stents (BP-DES) offer controlled drug elution and complete degradation of the polymer over time, eventually lowering the risk for chronic inflammation and neoatherosclerosis, which can be particularly helpful in patients with diabetes. While BP-DES and durable polymer drug-eluting stents (DP-DES) have demonstrated comparable efficacy in all-comers population, their efficacy and safety in patients with diabetes remains uncertain. Methods and results Electronic databases were systematically searched for randomized controlled trials (RCTs) comparing BP-DES with contemporary DP-DES in patients with diabetes. Study investigators were contacted to obtain additional data. The primary outcome was efficacy in terms of target-vessel revascularization (TVR) and target-lesion revascularization (TLR). We also evaluated the following safety outcomes separately: all-cause mortality, cardiac mortality, myocardial infarction (MI), and definite or probable stent thrombosis. Eleven RCTs including 5190 diabetic patients were included. At the longest available follow-up (mean 2.7 years), there was no significant difference in TLR [relative risk (RR): 1.02, 95% confidence interval (CI): 0.85-1.24; P = 0.80] or TVR (RR: 1.04, 95% CI: 0.81-1.34; P = 0.76). Safety outcomes of all-cause mortality, cardiac mortality, and MI were similar between the two groups. Stent thrombosis rates were also similar between BP-DES and DP-DES groups (1.66% vs. 1.83%; RR: 0.84, 95% CI: 0.54-1.31; P = 0.45). The heterogeneity was low and fixed-effect model yielded similar results. Meta-regression analysis showed no relationship between insulin requiring diabetes and difference in TLR or stent thrombosis between BP-DES and DP-DES. Conclusion Overall, BP-DESs have similar safety and efficacy profiles compared to contemporary DP-DES in patients with diabetes.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 50 条
  • [31] Safety and Efficacy of Biodegradable Drug-Eluting vs. Bare Metal Stents: A Meta-Analysis from Randomized Trials
    Yin, Yangguang
    Zhang, Yao
    Zhao, Xiaohui
    PLOS ONE, 2014, 9 (06):
  • [32] Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials
    Cassese, Salvatore
    Xhepa, Erion
    Ndrepepa, Gjin
    Kufner, Sebastian
    Colleran, Roisin
    Giacoppo, Daniele
    Koppara, Tobias
    Mankerious, Nader
    Byrne, Robert A.
    Laugwitz, Karl-Ludwig
    Schunkert, Heribert
    Fusaro, Massimiliano
    Kastrati, Adnan
    Joner, Michael
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2018, 19 (11) : 1294 - 1301
  • [33] A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials
    Lipinski, Michael J.
    Forrestal, Brian J.
    Iantorno, Micaela
    Torguson, Rebecca
    Waksman, Ron
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2018, 19 (01) : 5 - 11
  • [34] Polymer drug-eluting stents: is the future biodegradable?
    Waksman, Ron
    Maluenda, Gabriel
    LANCET, 2011, 378 (9807) : 1900 - 1902
  • [35] Improved clinical outcome with biodegradable polymer drug-eluting stents compared to durable polymer drug-eluting stents for primary percutaneous coronary intervention
    Andriyati, Ratna
    Firman, Doni
    Kurniawati, Yovi
    Alkatiri, Amir Aziz
    Pranata, Raymond
    Muliawan, Hary Sakti
    Rossimarina, Vienna
    Soerianata, Sunarya
    POSTGRADUATE MEDICAL JOURNAL, 2021, 97 (1152) : 638 - 643
  • [36] Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials
    Zhu, Yong
    Liu, Kesen
    Kong, Xiangyun
    Nan, Jing
    Gao, Ang
    Liu, Yan
    Han, Hongya
    Li, Hong
    Zhu, Huagang
    Zhang, Jianwei
    Zhao, Yingxin
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [37] Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up
    Wang, Qi
    Zhou, Yu
    Qiao, Tong
    Zhou, Min
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (04) : 1545 - 1556
  • [38] Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Drug-Eluting Stents for Patients With Coronary Artery Disease: An Update Meta-Analysis
    Yanyu Wang
    Pingshuan Dong
    Ling Li
    Xiaoling Li
    Hongyun Wang
    Xuming Yang
    Shaoxin Wang
    Zhuanzhen Li
    Xiyan Shang
    Cardiovascular Drugs and Therapy, 2014, 28 : 379 - 385
  • [39] Durable versus biodegradable polymer drug-eluting stents in all-comers
    Witzig, Thierry
    Puricel, Serban
    Witzig, Alain
    Meier, Pascal
    Arroyo, Diego
    Togni, Mario
    Cook, Stephane
    OPEN HEART, 2025, 12 (01):
  • [40] Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis
    Wu, James J.
    Way, Joshua A. H.
    Roy, Probal
    Yong, Andy
    Lowe, Harry
    Kritharides, Leonard
    Brieger, David
    HEALTH SCIENCE REPORTS, 2018, 1 (11)